Cibisatamab Biosimilar - Research Grade

Human

CEA + CD3

5mg/ml

Human IgG1-kappa/lambda with domain crossover, trivalent

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Functional Assays

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Detects human CEACAM5. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Cibisatamab.

Blue ice

Bridging CEA and CD3 redirects T cells against carcinoembryonic-antigen-positive tumours, an approach actively pursued in solid-tumour immunotherapy research. This research-grade reagent is an unconjugated, non-therapeutic analog of cibisatamab that engages human CEA and CD3 and is validated for functional assays. It is sold for research use only, formulated to a low-endotoxin standard suitable for in vivo studies, and produced in scalable milligram to gram quantities for high-throughput laboratories. Typical uses include T-cell redirection assays, bispecific-engager studies, in vitro cytotoxicity screening, and in vivo solid-tumour models.

Carcinoembryonic Antigen

P06731;P07766

ICH3002

https://www.imgt.org/mAb-DB/